PARP Inhibitor Biomarkers Market Size & Share 2026-2035

PARP Inhibitor Biomarkers Market Size

The global PARP inhibitor biomarkers market was valued at USD 1 billion in 2025 and is projected to grow from USD 1.1 billion in 2026 to USD 2.4 billion by 2035, expanding at a CAGR of 8.7%, according to the latest report published by Global Market Insights Inc.

This substantial growth is driven by numerous factors, such as the increasing prevalence of breast cancer, advancements in genomic technologies, and rising expenditure for cancer treatment.

PARP inhibitor biomarkers are genetic indicators, such as BRCA1/2 mutations and homologous recombination deficiencies (HRD), used to identify cancer patients who are most likely to respond to PARP inhibitor therapies. These biomarkers play a critical role in enabling targeted treatment and improving outcomes in precision oncology.

The increasing global prevalence of breast cancer is a major driver for the PARP inhibitor biomarkers market. According to the World Health Organization (WHO), breast cancer accounted for approximately 670,000 deaths worldwide in 2022 and was the most commonly diagnosed cancer among women in 157 out of 185 countries. This rising disease burden has intensified the need for effective, targeted treatment strategies. PARP inhibitors have emerged as a critical therapeutic option, particularly for patients with BRCA1/2 mutations and other homologous recombination repair deficiencies. As the number of breast cancer cases continues to grow, there is a parallel increase in demand for accurate biomarker testing to identify patients most likely to benefit from these targeted therapies. Advances in molecular diagnostics and genetic profiling further support this trend by enabling precise patient stratification. Consequently, the expanding breast cancer patient pool, combined with the growing adoption of precision oncology, is significantly accelerating the demand for PARP inhibitor biomarkers, driving sustained market growth.

Additionally, rising expenditure on cancer treatment is a key driver for the growth of the PARP inhibitor biomarkers market. Globally, the economic burden of cancer care continues to increase due to factors such as the rising incidence of cancer, adoption of advanced therapies, and prolonged treatment durations. High-cost targeted therapies, including PARP inhibitors, necessitate precise patient selection to ensure clinical effectiveness and cost efficiency. This has significantly increased the demand for biomarker testing to identify patients with specific genetic mutations, such as BRCA1/2, who are most likely to benefit from these treatments. Additionally, growing healthcare investments by governments and private organizations are supporting the integration of advanced diagnostic technologies into clinical practice. As healthcare systems aim to optimize treatment outcomes while managing costs, the emphasis on personalized medicine continues to grow, thereby driving the adoption of PARP inhibitor biomarkers across oncology settings.

PARP Inhibitor Biomarkers Market Trends

• Advancements in genomic technologies are significantly driving the growth of the PARP inhibitor biomarkers industry. Rapid improvements in next-generation sequencing (NGS) and high-throughput genetic testing have enabled the identification of key mutations such as BRCA1 and BRCA2 with greater accuracy and speed. Additionally, these technologies are reducing testing costs, making biomarker analysis more accessible across healthcare systems.
• Moreover, the integration of advanced bioinformatics tools with genomic platforms is enhancing the interpretation of complex genetic data. This enables clinicians to better identify patients who are most likely to respond to PARP inhibitor therapies. As a result, the increased efficiency and precision of genomic testing are accelerating biomarker adoption in clinical oncology practice.
• The growing adoption of personalized medicine and precision therapy is another major driver for the market. Healthcare providers are increasingly shifting from conventional treatment approaches to targeted therapies tailored to individual patient profiles. This trend has heightened the importance of biomarker-based diagnostics in determining the most effective treatment strategies.
• Additionally, precision medicine initiatives supported by governments and healthcare organizations are promoting the use of companion diagnostics, including PARP inhibitor biomarkers. Moreover, the rising awareness among clinicians and patients regarding the benefits of targeted therapies is further fueling demand, thereby contributing to sustained market expansion.

PARP Inhibitor Biomarkers Market Analysis

Based on product, the PARP inhibitor biomarkers market is divided into kits and assays. The kits segment of the market is forecasted to reach USD 1.5 billion by 2035, showcasing robust growth propelled by several key factors.

• The kits segment plays a crucial role in driving the PARP inhibitor biomarkers industry growth due to its ease of use and standardization in clinical settings. These kits offer ready-to-use solutions for biomarker detection, reducing complexity and turnaround time. Additionally, their widespread adoption in hospitals and diagnostic labs enhances testing efficiency and supports large-scale screening initiatives.
• The kits segment further strengthens its position due to continuous product innovation and regulatory approvals that ensure reliability and consistency. Additionally, manufacturers are focusing on developing user-friendly and automated kits that integrate seamlessly into existing laboratory workflows. This enhances efficiency and encourages broader adoption, thereby supporting sustained market expansion.
• The assay segment accounted for USD 397.5 million in 2025 and is projected to expand at a CAGR of 8.9% from 2026 to 2035. The assays segment is also contributing significantly to market expansion by providing flexible and customizable testing solutions. Moreover, assays enable in-depth analysis of genetic mutations and are frequently used in research settings. Their ability to support precise and sensitive detection strengthens their role in advancing biomarker-based diagnostics.

Based on service, the PARP inhibitor biomarkers market is bifurcated into breast cancer gene (BRCA) 1 & 2 testing, homologous recombination deficiency (HRD) testing, homologous recombination repair (HRR) testing, and other services. The breast cancer gene (BRCA) 1 & 2 testing segment accounted for USD 430.7 million in 2025.

• Breast cancer gene (BRCA) 1 & 2 testing holds a leading share in the market due to its established role in identifying patients eligible for PARP inhibitor therapies. These tests are widely used in clinical practice, particularly for breast and ovarian cancer patients. Additionally, strong clinical guidelines supporting BRCA testing further drive its adoption.
• Moreover, increasing genetic counseling services and awareness programs are encouraging patients to undergo early testing. This rising adoption enhances early diagnosis and targeted therapy selection, further propelling market growth.
• The homologous recombination deficiency (HRD) testing segment accounted for USD 297.9 million in 2025 and is projected to expand at a CAGR of 8.8% from 2026 to 2035. HRD testing is gaining traction as it helps identify homologous recombination deficiencies beyond BRCA mutations. Moreover, it expands the eligible patient pool for PARP inhibitor treatments, thereby increasing demand for advanced biomarker testing and supporting market growth.
• Additionally, its emerging role in precision oncology enhances treatment decision-making, thereby encouraging its integration into routine diagnostics.

Based on application, the PARP inhibitor biomarkers market is bifurcated into breast cancer, ovarian cancer, pancreatic cancer, prostate cancer, and other applications. The breast cancer segment accounted for USD 473.4 million in 2025.

• The breast cancer segment contributes significantly to market growth due to the high prevalence of the disease and increasing adoption of targeted therapies. Additionally, rising awareness and screening programs are boosting demand for biomarker testing in this segment.
• Additionally, advancements in screening technologies and rising survival rates are increasing the number of patients requiring biomarker testing. This sustained demand continues to drive growth within this segment.
• The ovarian cancer segment accounted for USD 284.9 million in 2025 and is projected to expand at a CAGR of 8.9% from 2026 to 2035. The ovarian cancer segment is also driving the market, as PARP inhibitors are widely used in its treatment, particularly in recurrent cases. Moreover, strong clinical evidence supporting their effectiveness increases the need for biomarker-based patient selection.
• The pancreatic cancer segment accounted for USD 96.4 million in 2025 and is expected to grow at a CAGR of 9.2% from 2026 to 2035. This growth is supported by the increasing adoption of precision medicine approaches in oncology. Additionally, the rising identification of BRCA mutations in pancreatic cancer patients is expanding the application of PARP inhibitor biomarker testing. This has enhanced the use of targeted therapies and improved treatment decision-making, thereby contributing to steady market expansion over the forecast period.

Based on technology, the PARP inhibitor biomarkers market is bifurcated into next-generation sequencing (NGS), polymerase chain reaction (PCR), immunohistochemistry (IHC), in situ hybridization (ISH), and other technologies. The next-generation sequencing (NGS) segment accounted for USD 542.5 million in 2025.

• Next-Generation Sequencing (NGS) is driving market growth by enabling comprehensive genetic profiling with high accuracy. Furthermore, its ability to detect multiple mutations simultaneously makes it highly valuable for PARP inhibitor biomarker testing.
• Next-generation sequencing (NGS) continues to gain traction due to its scalability and ability to support large-scale genomic studies. Additionally, increasing investments in genomic research and infrastructure are accelerating its adoption across clinical and research applications. This ongoing expansion strengthens its contribution to overall market growth.
• The PCR segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 8.1% over the forecast period. Polymerase Chain Reaction (PCR) technology continues to support the market due to its cost-effectiveness and rapid results. Moreover, it is widely used for targeted mutation detection, making it suitable for routine clinical applications.
• The immunohistochemistry segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 8.4% over the forecast period. Immunohistochemistry (IHC) is contributing to market expansion by allowing visualization of protein expression in tissue samples. Additionally, its role in supporting complementary biomarker analysis enhances its importance in clinical diagnostics.

Based on end use, the PARP inhibitor biomarkers market is bifurcated into hospitals and clinics, diagnostic laboratories, academic and research institutes, and other end users. The hospital and clinics segment accounted for USD 449 million in 2025.

• Hospitals and clinics account for a major share of the market due to their role as primary centers for cancer diagnosis and treatment. Additionally, the availability of advanced diagnostic infrastructure supports the adoption of biomarker testing in these settings.
• Moreover, these facilities are increasingly integrating personalized medicine approaches into clinical workflows. This enhances the utilization of PARP inhibitor biomarkers for treatment decision-making, further strengthening their position in the market.
• The diagnostic laboratories segment is anticipated to grow at a CAGR of 9.1% over the forecast period. Diagnostic laboratories are also playing a key role in market growth by offering specialized testing services. Additionally, their ability to handle high testing volumes and provide accurate results supports the expanding demand for biomarker analysis.

North America PARP Inhibitor Biomarkers Market

The North America region accounted for 40.7% of the market in 2025. The North America market is experiencing robust expansion.

• The U.S. PARP inhibitor biomarkers industry size reached USD 384.4 million in 2025, growing from USD 357.7 million in 2024, and is anticipated to grow at a CAGR of 8.4% from 2026 to 2035.
• The rising prevalence of breast cancer in North America is a major factor driving the demand for PARP inhibitor biomarkers. The region reports a significant number of breast cancer cases annually, creating a strong need for advanced diagnostic and treatment approaches. Additionally, increasing awareness and screening programs are contributing to higher diagnosis rates.
• Moreover, the growing burden of hereditary breast cancer cases, particularly those associated with BRCA mutations, is further accelerating the adoption of biomarker testing. This has increased the utilization of PARP inhibitors, which require precise patient selection. As a result, the reliance on biomarker-based diagnostics continues to expand.
• Additionally, well-established healthcare infrastructure and access to advanced genomic testing technologies support widespread adoption of PARP inhibitor biomarkers. The presence of leading pharmaceutical and diagnostic companies also enhances innovation, thereby strengthening market growth in the region.

Europe PARP Inhibitor Biomarkers Market

Europe market accounted for USD 232.2 million in 2025 and is anticipated to show lucrative growth over the forecast period.

• Advancements in genomic technologies are significantly contributing to the growth of the market in Europe. The increasing adoption of next-generation sequencing and molecular diagnostics has improved the detection of BRCA and other genetic mutations. Additionally, these technologies are enabling faster and more accurate diagnoses.
• Moreover, strong government support for genomic research and precision medicine initiatives is enhancing the integration of advanced testing methods into clinical practice. Programs promoting personalized healthcare are driving the use of biomarker-based diagnostics, further supporting market expansion.
• Furthermore, collaborations between research institutions and biotech companies are fostering innovation in genomic technologies. This continuous development is improving the accessibility and efficiency of biomarker testing, thereby accelerating demand for PARP inhibitor biomarkers across the region.

Asia Pacific PARP Inhibitor Biomarkers Market

The Asia Pacific region is projected to show a lucrative growth of about 9.1% during the forecast period.

• Rising healthcare expenditure for cancer treatment is a key driver for the PARP inhibitor biomarkers industry in Asia Pacific. Governments and private healthcare providers are increasingly investing in advanced cancer therapies, including targeted treatments. Additionally, expanding healthcare budgets are supporting the adoption of modern diagnostic solutions.
• Moreover, the growing economic burden of cancer is prompting healthcare systems to prioritize cost-effective treatment strategies. Biomarker testing helps identify patients who will benefit most from expensive therapies like PARP inhibitors, thereby improving treatment efficiency and outcomes.
• In addition, increasing insurance coverage and improving healthcare infrastructure in emerging economies are enhancing access to advanced diagnostics. This is encouraging the integration of biomarker testing into routine cancer care, further driving market growth in the region.

Latin America PARP Inhibitor Biomarkers Market 

Brazil is experiencing significant growth in the PARP inhibitor biomarkers industry.

• The growing adoption of personalized medicine is a key factor driving the Brazil market. Healthcare providers are increasingly shifting towards targeted therapies tailored to individual genetic profiles. Additionally, this approach improves treatment outcomes and reduces unnecessary interventions.
• Moreover, rising awareness about precision therapy among clinicians and patients is boosting the demand for biomarker-based diagnostics. The use of PARP inhibitors in patients with specific genetic mutations has increased significantly, thereby supporting market expansion.
• Furthermore, government initiatives and investments aimed at improving cancer care are promoting the adoption of advanced diagnostic technologies. This ongoing transition toward personalized healthcare is strengthening the demand for PARP inhibitor biomarkers in Brazil.

Middle East and Africa PARP Inhibitor Biomarkers Market 

• The increasing prevalence of breast cancer in Saudi Arabia is driving the demand for PARP inhibitor biomarkers. Breast cancer remains one of the most commonly diagnosed cancers in the country, leading to a growing need for early detection and targeted therapies. Additionally, national awareness campaigns are improving diagnosis rates.
• Moreover, a rising number of patients with genetic mutations such as BRCA1 and BRCA2 is increasing the adoption of biomarker testing. This is essential for identifying candidates suitable for PARP inhibitor therapies. As a result, demand for advanced diagnostic solutions continues to rise.
• In addition, government initiatives to strengthen oncology care and improve healthcare infrastructure are supporting the integration of precision medicine. The availability of specialized cancer centers and diagnostic facilities is further promoting the use of PARP inhibitor biomarkers, thereby driving market growth.

PARP Inhibitor Biomarkers Market Share

• The top five players, Illumina Inc., Thermo Fisher Scientific, Foundation Medicine, QIAGEN, and Myriad Genetics, collectively accounted for approximately 52% share of the global PARP inhibitor biomarkers industry, reflecting strong influence driven by advanced genomic technologies, established companion diagnostics capabilities, extensive clinical adoption, and expanding precision oncology applications across developed and emerging regions.
• PARP inhibitor biomarker solution providers and diagnostic companies are increasingly focusing on technological innovation, accuracy enhancement, and clinically relevant test development to improve cancer diagnosis and treatment outcomes. Key areas of emphasis include advanced genomic profiling technologies, next-generation sequencing (NGS), PCR-based assays, and multiplex testing platforms to enable precise detection of BRCA1/2 and homologous recombination deficiency (HRD) biomarkers. Additionally, companies are enhancing test sensitivity, turnaround time, and user-friendly reporting systems to support clinical decision-making. Parallel investments in product standardization, automation, and sample stability are ensuring consistent performance across hospitals, diagnostic laboratories, and research settings.
• Companies, pharmaceutical firms, diagnostic developers, and healthcare providers are strengthening strategic collaborations to expand access to PARP inhibitor biomarkers and promote their clinical adoption. Partnerships with oncology centers, research institutes, and genomic testing laboratories are improving awareness and utilization of biomarker-based testing in cancer treatment. Moreover, collaborations with biotech firms and drug developers support the integration of companion diagnostics with PARP inhibitor therapies. These initiatives enhance patient access to targeted treatments, improve diagnostic accuracy, and support precision oncology approaches, thereby contributing significantly to the growth of the market across developed and emerging regions.

PARP Inhibitor Biomarkers Market Companies

Few of the prominent players operating in the PARP inhibitor biomarkers industry include:

• Agilent Technologies
• Ambry Genetics
• Amoy Diagnostics
• BPS Bioscience
• EntroGen
• Foundation Medicine
• Guardant Health
• Illumina Inc.
• Invitae
• Myriad Genetics
• Pillar Biosciences
• QIAGEN
• Thermo Fisher Scientific
   
• Myriad Genetics

Ubio Biotechnology Systems strengthens its position in the PARP inhibitor biomarkers market through innovative rapid diagnostic technologies, a diversified reproductive health portfolio, and an expanding presence across emerging and developed healthcare markets.

• QIAGEN

QIAGEN strengthens its position through robust molecular testing capabilities, reliable PCR-based diagnostic solutions, and a strong presence in clinical laboratories, supporting efficient biomarker identification and driving adoption of precision medicine in oncology care.

PARP Inhibitor Biomarkers Industry News

• In January 2024, Myriad Genetics, Inc., a prominent figure in genetic testing and precision medicine, finalized an agreement to acquire specific assets from Intermountain Precision Genomics’ (IPG) laboratory division. These assets included the Precise Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory located in St. George, Utah. This strategic acquisition is expected to bolster Myriad Genetics' market presence in genetic testing and precision medicine, positioning the company competitively within the industry.

The PARP inhibitor biomarkers market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million and from 2022 – 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Kits
• Assays

Market, By Service

• Breast cancer gene (BRCA) 1 & 2 testing 
• Homologous recombination deficiency (HRD) testing 
• Homologous recombination repair (HRR) testing
• Other services

Market, By Technology

• Next-generation sequencing
• Polymerase Chain Reaction
• Immunohistochemistry
• In situ hybridization
• other technologies

Market, By Application

• Breast cancer
• Ovarian cancer
• Pancreatic cancer
• Prostate cancer
• Other applications 

Market, By End use

• Hospitals and clinics
• Diagnostic laboratories
• Academic and research institutes
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE